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Abstract
Background: Most previous studies of the CpG island methylator phenotype (CIMP) in colorectal cancer (CRC) have 
been conducted on a relatively small numbers of CpG sites. In the present study we performed comprehensive DNA 
methylation profiling of CRC with the aim of characterizing CIMP subgroups.
Methods: DNA methylation at 1,505 CpG sites in 807 cancer-related genes was evaluated using the Illumina 
GoldenGate® methylation array in 28 normal colonic mucosa and 91 consecutive CRC samples. Methylation data was 
analyzed using unsupervised hierarchical clustering. CIMP subgroups were compared for various clinicopathological 
and molecular features including patient age, tumor site, microsatellite instability (MSI), methylation at a consensus 
panel of CpG islands and mutations in BRAF and KRAS.
Results: A total of 202 CpG sites were differentially methylated between tumor and normal tissue. Unsupervised 
hierarchical clustering of methylation data from these sites revealed the existence of three CRC subgroups referred to 
as CIMP-low (CIMP-L, 21% of cases), CIMP-mid (CIMP-M, 14%) and CIMP-high (CIMP-H, 65%). In comparison to CIMP-L 
tumors, CIMP-H tumors were more often located in the proximal colon and showed more frequent mutation of KRAS 
and BRAF (P < 0.001).
Conclusions: Comprehensive DNA methylation profiling identified three CRC subgroups with distinctive 
clinicopathological and molecular features. This study suggests that both KRAS and BRAF mutations are involved with 
the CIMP-H pathway of CRC rather than with distinct CIMP subgroups.
Background
DNA hypermethylation-induced gene silencing is a com-
mon event in many malignancies and serves as an alter-
native mechanism to genetic mutation for the loss of
tumor suppressor functions [1,2]. Although the mecha-
nisms that underlie aberrant DNA methylation in cancer
cells remain to be elucidated, current evidence suggests
that it may be an early and possibly even an initiating
event in the development of colorectal cancer (CRC).
A subset of CRC has been shown to exhibit frequent
and concurr ent h ypermet h yla tion a t specific gene pro-
moters and is referred to as the CpG island methylator
phenotype (CIMP+) [3]. CIMP+ CRC is associated with
distinct clinicopathological and molecular features
including proximal tumor location, preponderance in
elderly females, poorly differentiated and mucinous
tumor histology, microsatellite instability (MSI) and fre-
quent BRAF V600E mutation [3-10]. CIMP+ CRC often
lack the hallmark genetic alterations in APC, p53 and 18q
that characterize the classic adenoma-carcinoma
sequence. Instead, CIMP+ tumors are thought to develop
along an alternate serrated adenoma pathway in which
hypermethylation rather than mutation is used to inacti-
vate tumor suppressor genes [11].
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In an effort to establish CIMP+ CRC as a distinct sub-
group of CRC, Laird and colleagues analysed the methy-
lation of 195 individual gene promoter regions in 295
CRC using the quantitative MethyLight assay [10]. From
their results, they proposed a panel of 5 CpG island meth-
ylation markers to standardize the classification of
CIMP+ CRC. However, different groups have continued
to use a variety of methylation markers to define CIMP+
CRC [7,12-14]. The lack of consensus markers has led to
reports of several CIMP subgroups according to the fre-
quency of CpG island methylation [13-15]. The investiga-
tors who originally proposed CIMP recently described
two subgroups of CIMP+, termed CIMP-1 and CIMP-2,
that displayed increased frequencies of BRAF and KRAS
mutations, respectively [14]. Similarly, Nagasaka et al
described two distinct patterns of gene methylation in
CRC that also segregated with BRAF and KRAS muta-
tions [13,16]. Using a panel of 8 methylation markers,
Ogino et al identified a CRC subgroup which they termed
CIMP-low that was associated with frequent KRAS muta-
tion, MGMT methylation and occurrence in males [17].
Most previous studies of CIMP+ CRC have investigated
a relatively small number of CpG island markers for
methylation. The GoldenGate Methylation BeadArray
(Illumina, Inc.) technology provides the opportunity for
high-throughput methylation analysis of a large number
of CpG sites. In the present study the GoldenGate Methy-
lation Cancer Panel I containing 1,505 CpG loci within
807 cancer-related genes was used to study methylation
p a t t e r n s  i n  9 1  u n s e l e c t e d  C R C .  T h e s e  g e n e s  w e r e
selected based on their involvement in cell growth con-
trol, differentiation, migration, apoptosis, DNA damage
repair and oxidative metabolism. The GoldenGate tech-
n o l o g y  a l l o w e d  u s  t o  i d e n t i fy  t h r e e  d i s t i n c t  C R C  s u b -
groups according to their methylation pattern which
showed distinctive clinicopathological and molecular
characteristics and differed in their frequencies of BRAF
and KRAS mutation.
Methods
Tissue samples
Unselected cases of CRC and adjacent normal colonic
mucosa were obtained from 91 patients undergoing sur-
gical resection at St John of God Hospital, Subiaco, West-
ern Australia. All samples were snap-frozen in liquid
nitrogen at the time of surgery and stored at -80°C until
use. This set of tumors contains well-annotated clinico-
pathological information including age, gender, tumor
location, staging, presence of lymphocytic infiltration and
careful pathological assessment of perineural (PNI), lym-
phovascular (LVI) and extramural invasion (EMVI).
Informed consent was obtained from all patients and the
project was approved by the Human Research Ethics
Committee of St John of God Hospital.
BRAF mutation, KRAS mutation and microsatellite 
instability
DNA was extracted from approximately 25 mg of tissue
using standard phenol-chloroform extraction. Hotspot
mutations in BRAF (V600E) and KRAS (codons 12 and
13) were identified using fluorescent single strand confor-
mation polymorphism (F-SSCP) as described previously
[18,19]. Deletions in the BAT-26 mononucleotide repeat
were detected using F-SSCP and this was used to estab-
lish MSI+ status [20].
MethyLight determination of CIMPW status
Sodium bisulfite modification was performed using the
EZ DNA methylation kit according to the manufacturer's
instructions (Zymo Research, Orange, CA) and eluted
into 20 μl of 10 mmol/L Tris-HCl (pH 8). The required
amount of genomic DNA to ensure reliable evaluation of
DNA methylation following bisulfite modification was
determined as described previously [21]. DNA methyla-
tion levels for the panel of markers (RUNX3, CACNA1G,
IGF2, NEUROG1, SOCS1) described by Weisenberger et
al [10] were measured using MethyLight as described by
the authors. The percentage of methylated reference
(PMR) was calculated and normalised against β-actin to
account for variability in the amount of input bisulfite-
treated DNA. SssI methylase-treated DNA was used as
the methylated standard. A threshold PMR value of > 4
was  u s ed  t o  c las s i fy  l oci  as  m e t h y l a t ed  o r  n o n - m e t h y-
lated. In the present study, CIMPW refers to the classifica-
tion of CIMP using the panel of markers described by
Weisenberger et al., whereby CIMPW-high is defined as 3
or more methylated loci, CIMPW-low as 1 or 2 methy-
lated loci and CIMPW-negative as no methylated loci.
DNA methylation profiling using Illumina GoldenGate® 
methylation bead array
Comprehensive DNA methylation profiling using the
Illumina Goldengate Methylation Arrays® (Illumina, San
Diego, CA) was carried out as described by Bibikova et al
[22] on 91 CRC and 28 randomly selected, matched nor-
mal colonic mucosa samples. Briefly, DNA was quantified
by real-time PCR and treated with bisulfite as for the
MethyLight assay. Human sperm DNA and Universal
methylated DNA (Chemicon, Temcula, CA) were
i n c l u d e d  i n  e a c h  r u n  a s  u n m e t h y l a t e d  a n d  m e t h y l a t e d
controls, respectively. The bisulfite-converted DNA was
probed at 1,505 individual CpG loci contained within 807
genes in the GoldenGate Methylation Cancer Panel I
according to the manufacturer's instructions (Illumina).
Hybridised arrays were scanned using the BeadArray
Reader (Illumina). Extraction and normalization of inten-
sity data was performed using the Beadscan software. To
ensure adequate sample quality, only samples having >Ang et al. BMC Cancer 2010, 10:227
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75% loci with a detection P-value of < 0.05 were included
for analysis.
Statistical analysis
The methylation level at each CpG site, or β-value, was
defined as the ratio of methylated allele to the sum of
methylated and unmethylated alleles and ranged from 0
(completely unmethylated) to 1 (completely methylated).
Normalisation of background intensity was estimated
from a set of built-in negative controls and subtracted
from each methylation data point as performed in other
studies [23,24]. All statistical analyses were carried out
using β-value as a continuous variable unless specified
otherwise. To compare the number of methylated genes
between different tumor subgroups, β-values were bina-
rized using a methylated threshold of 0.297. Using this
threshold, methylated controls in the array were classified
as unmethylated at a 5% false discovery rate. A total of 84
CpG sites contained within 39 X-chromosome genes
w e r e  e x c l u d e d  f r o m  t h e  a n a l y s i s  i n  o r d e r  t o  e l i m i n a t e
gender-specific bias.
Unsupervised and supervised hierarchical clustering
analyses were performed with the heatmap.2 function in
the gplots library. Unsupervised clustering was used to
characterize methylation patterns in an unbiased fashion,
as performed in other studies using methylation arrays
[14,25-27]. Supervised clustering analysis was used to
further investigate methylation differences observed in
unsupervised clustering. The optimal number of clusters
was determined using the Hubert & Levine internal clus-
ter quality index [28]. The robustness of this number was
evaluated by bootstrap resampling analysis (n = 1000).
Additional evidence to support the delineation of clusters
was obtained through unsupervised principal component
analysis. The frequency and level of CpG methylation
across different clusters was compared using a two-sam-
ple proportion test based on both binarised and continu-
ous β-values. The association of clinicopathological and
molecular variables with each cluster was analysed using
continuous β-values and the two-sample proportion t-
test. All statistical analyses were performed in R version
2.7.1 (The R Foundation for Statistical Computing) at 5%
significance level unless otherwise stated. Where applica-
ble, Bonferroni correction was applied to adjust for mul-
tiple testing.
Results
DNA methylation patterns in normal and tumor tissue
Unsupervised hierarchical clustering of DNA methyla-
tion data from 1,505 CpG sites in 28 samples of normal
colonic mucosa revealed no distinct clusters [Additional
file 1]. As expected, the methylation status of 84 CpG
sites in 39 genes located in the X-chromosome was per-
fect ly corre la t ed wit h gender [A dditional file 1]. T hese
genes were excluded from subsequent analyses. For the
91 tumor samples, three clusters were observed when
methylation data from all 1,505 loci were included in the
analysis [Additional file 2].
A total of 202 CpG sites, corresponding to 132 genes
(90 hypermethylated and 42 hypomethylated), were dif-
ferentially methylated between tumor and normal colonic
mucosa (P < 0.001, FDR 5%) [Additional file 3]. Unsuper-
vised hierarchical clustering of methylation data from
these 202 tumor-specific markers identified three major
tumor groups (Fig. 1), referred to here as CIMP-high
(CIMP-H; 59/91, 65%), CIMP-mid (CIMP-M; 13/91,
14%) and CIMP-low (CIMP-L; 19/91, 21%). The mean
methylation level (β-value) of the 202 CpG sites for these
groups was 0.617, 0.506 and 0.370, respectively (P  <
0.001). Binarization of the methylation readings using a
β-value cut-off of 0.297 revealed a decreasing number of
methylated CpG sites for the three groups (167, 136 and
105 respectively; P < 0.001).
Although branching of the dendogram suggested the
existence of two subgroups within CIMP-H (Fig. 1), the
mean methylation level and the frequency of methylation
between these groups were not significantly different (P =
0.37 and P = 0.90 respectively). Additional evidence for
the validity of tumor segregation was obtained through
unsupervised principal component analysis (PCA) [Addi-
tional file 4]. CIMP-H could be clearly segregated from
CIMP-L. CIMP-H and CIMP-M could also be discrimi-
nated from each other, although less distinctly. This is
presumably because of a greater similarity between these
two groups [Additional file 4]. In further support, 3 was
the most frequent optimal number of clusters in boot -
strap resampling analysis.
CIMP subgroups show distinctive clinicopathological and 
molecular features
The distribution of clinicopathological and molecular
features for 91 CRC in relation to the methylation pattern
obtained from analysis of all 202 differentially methylated
CpG sites is shown in Fig. 1. Calculation of associations
between these features and the three CIMP subgroups
are shown in Table 1. Similar to previous reports on
CIMP+, the CIMP-H tumors in this study were signifi-
cantly associated with older age, proximal tumor location
and  BRAF  mutation relative to CIMP-M and CIMP-L
tumors. CIMP-H was also significantly associated with
MSI+ when compared to CIMP-M, but not CIMP-L
tumors. Two of the 15 MSI+ tumors were observed in the
CIMP-L group and 13 in the CIMP-H group. Interest-
ingly, the two patients with CIMP-L MSI+ tumors were
aged 44 and 60 years, suggesting the underlying cause of
the MSI+ phenotype was germline or somatic mutation
of the mismatch repair genes rather than hMLH1 methy-
lation. Indeed, no hMLH1 methylation was detected inAng et al. BMC Cancer 2010, 10:227
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both these cases in the GoldenGate Methylation Array
data.
All 16 tumors classified as CIMPW-high by Methylight
analysis using the panel of markers proposed by Weisen-
berger et al (>3/5 sites methylated) were contained within
the CIMP-H group, while all 18 tumors classified as
CIMPW-low (1/5 or 2/5 sites methylated) segregated into
the CIMP-H or CIMP-M groups. Unfortunately, CpG
sites for only 2 (RUNX3,  IGF2) of the 5 genes in the
CIMPW panel were included in the Golden Gate arrays,
thus preventing comparison of CIMP status by array and
Methylight analysis. Nevertheless, there was good corre-
lation between the array and Methylight methods for
methylation levels of RUNX3 and IGF2 (all p < 0.05) using
Pearson correlation.
All 15 tumors with BRAF mutation were CIMP-H. A
significantly higher frequency of KRAS  mutation was
observed in CIMP-H compared to CIMP-L or CIMP-M
tumors. None of the 13 CIMP-M tumors contained a
KRAS  mutation. The presence of extramural vascular
invasion (EMVI) was more frequent in CIMP-M com-
pared to CIMP-H or CIMP-L tumors. The presence of a
tumor-infiltrating lymphocytic response (TILS) was not
associated with any of the CIMP subgroups.
Differentially methylated genes in CIMP subgroups
Five clusters of CpG loci, termed A to E, were apparent
following unsupervised hierarchical clustering of methy-
lation data for the 202 CpG loci that showed tumor-spe-
cific methylation (Fig. 1). CpG sites in clusters A and C
were more highly methylated in CIMP-M and CIMP-H
Figure 1 Unsupervised hierarchical clustering of 202 tumor-specific probes (rows) in 91 CRC (columns). The 3 tumor clusters generated by this 
analysis were termed CIMP-High (CIMP-H), CIMP-Mid (CIMP-M) and CIMP-Low (CIMP-L). Clinicopathological and molecular features are shown above 
the heatmap. White rectangles are cases with missing data. Gender: female (red), male (blue); Age: ≥ 67 years (red), < 67 (blue); Tumor location: prox-
imal (red), distal (blue); Tumor stage (ACPS): A or B (blue), C or D (red); Lymphovascular invasion (LVI): present (red), absent (blue); Extramural vascular 
invasion (EMVI): present (red), absent (blue); Perineural invasion (PNI): present (red), absent (blue); Tumor infiltrating lymphocytes (TILS): present (red), 
absent (blue); CIMPW: CIMPW-high (red), CIMPW-low (yellow), CIMPW-negative (blue); BRAF: mutant (red), wildtype (blue); KRAS: mutant (red), wildtype 
(blue); Microsatellite instability (MSI): positive (red), negative (blue). Five CpG clusters (A-E) were apparent from the analysis and showed differential 
methylation amongst the 3 CIMP subgroups.
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tumors compared to CIMP-L tumors, while the converse
was true for the CpG sites in cluster D. CpG sites in clus-
ter B and cluster E showed uniformly high and low meth-
ylation, respectively, in each of the 3 CIMP subgroups.
Using published data from studies on human stem cells
[29], 50% (39/98) of the genes within clusters A and C
were found to be targets for binding by Polycomb repres-
sive complex 2 (PRC2) components and/or H3K27 trim-
ethylation. In contrast, only 12% (5/41) of the genes
within clusters B, D and E were targets (P < 0.001). These
observations support previous reports that hypermethy-
lated genes in cancer are frequent targets of PRC2-medi-
ated H3K27 trimethylation [30].
Discussion
The current study is the first to use array-based technol-
ogy to enable comprehensive methylation profiling of
CRC. A total of 1,505 CpG sites contained within 807
genes were assessed in 91 consecutive cases of CRC. The
GoldenGate® arrays employed here were recently used to
Table 1: Clinicopathological and molecular characteristics of CIMP subgroups.
CIMP subgroup (n, %) P
LMH L vs MM   vs HL   vs H
19 (21) 13 (14) 59 (65)
Female 6 (32) 4 (31) 30 (51)
Male 13 (68) 9 (69) 29 (49) 0.952 0.211 0.175
Age ≥ 67 years 6 (32) 5 (38) 37 (63)
Age < 67 years 13 (68) 8 (62) 22 (37) 0.570 0.003 0.012
Proximal tumor 
site1
5 (26) 1 (8) 29 (49)
Distal tumor site2 14 (74) 12 (92) 29 (49) 0.152 < 0.001 0.001
ACPS Stage A or B 8 (42) 4 (31) 36 (61)
ACPS Stage C or D 11 (58) 9 (69) 23 (39) 0.520 0.025 0.105
LVI Negative 15 (79) 6 (46) 39 (66)
LVI Positive 4 (21) 7 (54) 20 (34) 0.049 0.188 0.126
EMVI Negative 19 (100) 8 (62) 52 (88)
EMVI Positive 0 (0) 5 (38) 7 (12) 0.005 0.031 0.024
PNI Negative 17 (89) 11 (85) 52 (88)
PNI Positive 2 (11) 2 (15) 7 (12) 0.744 0.506 0.708
TILS Negative3 9 (47) 5 (38) 26 (44)
TILS Positive 7 (37) 8 (62) 33 (56) 0.326 0.547 0.521
CIMPW - negative4 19 (100) 10 (77) 28 (47)
CIMPW - low 0 (0) 3 (23) 15 (25)
CIMPW - high 0 (0) 0 (0) 16 (27) 1.000 < 0.001 < 0.001
MSI+ 2 (11) 0 (0) 13 (18)
MSI- 17 (89) 13 (100) 46 (78) 0.125 < 0.001 0.221
BRAF mutant 0 (0) 0 (0) 15 (25)
BRAF wildtype 19 (100) 13 (100) 44 (75) 1.000 < 0.001 < 0.001
KRAS mutant 3 (16) 0 (0) 26 (44)
KRAS wildtype 16 (84) 13 (100) 33 (56) 0.057 < 0.001 0.014
L, CIMP-low; M, CIMP-mid; H, CIMP-high; LVI, lymphovascular invasion; EMVI, extramural vascular invasion; PNI, perineural invasion; TILS, 
tumour infiltrating lymphocytes; CIMPW, classification of CIMP using the Weisenberger et al panel, whereby CIMPW-high is defined as 3 or 
more methylated loci, CIMPW-low as 1 or 2 methylated loci and CIMPW-negative as no methylated loci. MSI, microsatellite instability; 1Tumor 
location was unknown for 1 patient in CIMP-H, 2Number of distal CRC that were located at rectal site were 13, 1 and 11 in CIMP-L, CIMP-M and 
CIMP-H respectively, 3TILS data unknown for 3 patients in CIMP-L, 4P value for CIMPW was generated from comparison between CIMPW-high 
and CIMPW-low or CIMPW-negative.Ang et al. BMC Cancer 2010, 10:227
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profile methylation in head and neck cancer [31], renal
cancer [32], glioblastoma [33] and hematological neo-
plasms [24,27]. The validity of these arrays for the quanti-
tative assessment of methylation was shown in several
previous studies by comparison with other quantitative
methods [23,26,34]. The finding that methylation of CpG
sites in X-linked genes correlated with gender provided
further validation [Additional file 1]. Many of the genes
found to be hypermethylated in this study were previ-
ously reported to be methylated in CRC [Additional file
5]. Finally, in agreement with earlier work on cancer [30],
many of the genes showing de novo hypermethylation in
t h i s  s t u d y  o f  C R C  ( c l u s t e r  A  a n d  C  g e n e s,  F i g.  1 )  a r e
known targets for PRC2 [29].
Similar to earlier studies in CRC that evaluated a lim-
ited number of methylation markers [3-10], comprehen-
sive methylation profiling in the present study revealed
the existence of distinct tumor subgroups (Fig. 1). The
three major subgroups identified by unsupervised hierar-
chical clustering were classified as CIMP-H, CIMP-M
and CIMP-L according to the level and frequency of
methylation. In agreement with previous studies, CIMP-
H tumors were associated with older patient age, proxi-
mal site and BRAF  mutation (Table 1). All 16 tumors
identified as CIMPW-high using a proposed consensus
panel of 5 markers were contained within the CIMP-H
group, as well as all 15 tumors containing a BRAF muta-
tion. Using small numbers of methylation markers in
unselected CRC, the original studies by Toyota et al
reported CIMP+ frequencies of 62% [3] and 51% [35]
whereas subsequent studies reported lower frequencies
of 15-32% [5,7-10], [14]. In contrast, by investigating a
large number of methylation sites and using unsuper-
vised hierarchical clustering to analyze the results, we
observed a relatively high proportion (65%) of CIMP-H
tumors in the present study.
Previous studies have reported inconsistent results for
the association between CpG island methylation and
KRAS mutation [8,13,17,35,36], probably because of the
different methylation markers used in each study. Analy-
sis of a large number of CpG sites in the present study
revealed that CIMP-H tumors showed a significantly
higher  KRAS  mutation frequency compared to both
CIMP-M and CIMP-L tumors (Table 1). This result
agrees with some studies [4,5,8,35] but not others that
found an inverse association between KRAS  mutation
and CIMP+ [7,9,10].
Since  BRAF  mutations are strongly associated with
CIMP and mutually exclusive to KRAS mutations ([10];
Fig. 1), a point of interest is whether methylation patterns
differ between tumors with BRAF and KRAS mutations.
Supervised clustering analysis with Bonferroni correction
revealed that only 1 of the 202 tumor-specific CpG sites
was differentially methylated between these tumor
groups (HTR1B_P222_F, upregulated in BRAF  mutant
tumors,  p  = 8.1 × 10-6). HTR1B (5-hydroxytryptamine
(serotonin) receptor 1B) is a G protein-coupled multi-
pass membrane protein involved in regulation of the
serotonin system [37]. The gene is hypermethylated in
lung cancer and its chromosome locus (16q14.1) is fre-
quently deleted in a number of cancer types [38]. How-
ever, no links with BRAF or RAS mutations or signaling
have been reported.
A novel finding of this array-based analysis was the
existence of an apparent CIMP-M group (Fig. 1). These
tumors displayed a higher frequency of EMVI compared
to both CIMP-L and CIMP-H, and a significantly higher
stage compared to CIMP-H (Table 1). CIMP-M tumors
were almost exclusively located in the distal colon or rec-
tum (12/13, 92%). MSI and KRAS and BRAF mutations
were notably absent in these tumors, although this may
be due to reportedly lower frequencies of these altera-
tions in distal tumors [39]. Taken together, these results
suggest CIMP-M tumors could be a distinct clinical and
molecular entity, although confirmation in larger, inde-
pendent tumor series is required.
After adjustment for multiple testing, 170 CpG sites
were hypermethylated in CIMP-H compared to CIMP-L.
The 112 genes containing these CpG sites are ranked
according to significance in Additional file 5. Of these, 54
were previously reported as methylated in cancer, 38 as
methylated in gastrointestinal cancers and 30 in CRC
[Additional file 5]. Of the top 10 genes that were hyperm-
ethylated in CIMP-H compared to CIMP-L tumors, 5
have previously been implicated in the pathogenesis of
gastrointestinal tumors (NTRK3,  HS3ST2,  TWIST1,
CD40 and EYA4). Somatic mutation of NTRK3 has been
reported in human colon cancer [40], while methylation
of EYA4 has been documented previously in ulcerative
colitis-associated dysplasia [41] and CRC [42].
CIMP-M tumors were found to have a relatively high
incidence of EMVI (38%) compared to CIMP-H and
CIMP-L tumors (Table 1). Supervised analysis revealed
that HS3ST2, also known as 3-OST-2, was the only gene
to be differentially methylated between tumors showing
presence or absence of EMVI. Methylation-associated
silencing of HS3ST2 expression has been demonstrated in
breast, lung, pancreatic and colon cancers [43]. This gene
encodes an enzyme that modifies heparin sulfate proteo-
glycans [44] involved in cell adhesion and migration [45],
thus suggesting a possible mechanistic link between
HS3ST2 methylation and EMVI.
The use of Illumina GoldenGate® Beadarray technology
in this study allowed a large number of CpG sites to be
evaluated for methylation in an unbiased fashion. How-
ever, there are several limitations with this approach for
the characterization of CIMP subgroups in CRC. Firstly,
only a small fraction of all genes were investigated forAng et al. BMC Cancer 2010, 10:227
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methylation and in 70% of these just one CpG site per
gene was evaluated. Secondly, it is unclear whether the
methylation level at these sites relates to expression of the
genes. Thirdly, some of the probes used in this assay con-
tain single nucleotide polymorphisms (SNPs) or repeti-
tive elements that could influence methylation analysis
[25]. The cost effectiveness of using arrays to characterize
CIMP-H is questionable, given the strong concordance
between CIMP-H from this study and CIMPw. Further
studies should clarify if the additional information pro-
vided by methylation arrays is worth the complexity and
expense.
Conclusions
Methylation profiling of 807 cancer-related genes
revealed the presence of three CRC subgroups with dis-
tinct clinicopathological and molecular features. Similar
to earlier studies that investigated fewer methylation
markers, CIMP-H CRC were associated with older
patient age, proximal location and mutations in BRAF
and KRAS. Further investigations in large and indepen-
dent population-based series are required to validate
these findings and to assess the clinical utility of CIMP
subgroups.
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